A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder
- 334 Downloads
Seasonal affective disorder (SAD) is a relatively common cyclical depressive illness characterized by seasonal depressions during winter. The disorder is commonly responsive to light therapy, but antidepressant drug efficacy has not been definitely established. Serotonin selective re-uptake inhibitors are potentially efficacious treatments for SAD.
The objective of this study was to evaluate the efficacy, tolerability and safety of sertraline treatment for SAD.
One hundred and eighty seven outpatients with seasonal pattern recurrent winter depression (DSM-III-R defined) and a minimum 29-item Hamilton depression scale (SIGH-SAD version) score of 22 were randomized to 8 weeks treatment with either sertraline or placebo in a double-blind, multi-country, multi-center, parallel-group, flexible dose (50–200 mg once daily) study. Efficacy was investigated using physician and patient-rated scales measuring depression, anxiety and symptoms characteristic of seasonal affective disorder.
Sertraline produced a significantly greater response than placebo at endpoint as measured by changes in the 29-item and 21-item Hamilton depression scales, the clinical global impression (CGI) severity scale, the Hamilton anxiety scale, and the hospital anxiety and depression scale. The proportion of sertraline-treated subjects achieving a response on the CGI improvement rating (ratings of 1 or 2) at endpoint (last observation carried forward) was significantly greater than that of the placebo group. Overall sertraline was well tolerated with the most frequent placebo adjusted adverse events, being nausea, diarrhea, insomnia and dry mouth. Adverse events were mostly mild to moderate and transient.
Sertraline pharmacotherapy has been demonstrated to be an effective and well-tolerated therapy for out patients with SAD. As such, sertraline offers an important pharmacological option in the clinical management of this condition.
KeywordsSeasonal affective disorder Sertraline Reversed vegetative symptoms
This study was supported by grants from Pfizer International Inc. Scott Patten, MD, PhD, for his review of the manuscript. Dr Lane was formerly an employee of Pfizer Pharmaceuticals.
- Guy W (1976) ECDEU assesment manual for psychopharmacology, revised edn. US Dept of Health, Education and Welfare Publication (ADM) 91–338. National Institute of Mental Health, Rockville, MDGoogle Scholar
- Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55Google Scholar
- Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62Google Scholar
- Kasper S, Neumeister A (1995) Treatment indications for light therapy. Acta Neuropsychiatr 7:44–46Google Scholar
- Keller MB, Gelenberg AJ, Hirschfeld RMA, Rush, AJ, Thase ME, Kocsis JH, Markowitz JC, Fawcett JA, Koran LM, Klein DN, Russell JM, Kornstein SG, McCullough JP, Davis SM, Harrison WM (1998) The treatment of chronic depression. Part 2. A double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 59:598–607PubMedGoogle Scholar
- Koe BK, Weissman A, Welch WM, Browne RG (1983) Sertraline: a new selective inhibitor of serotonin uptake. Psychopharmacol Bull 19:687–691Google Scholar
- Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Pirker W, Brücke T, Kasper S (2000) Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by (123I)-2β-carbomethoxy-3β(4-iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry 47:158–160CrossRefPubMedGoogle Scholar
- Partonen T (1994) Pharmacotherapy of winter seasonal affective disorder: a review. Psychiatria Fennica 25:67–72Google Scholar
- Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J (1990) Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 51[Suppl B]:18–27Google Scholar
- Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T, Moller H-J (1993) Fluoxetine as a treatment alternative to light therapy in seasonal affective disorder (SAD). Pharmacopsychiatry 26:193Google Scholar
- Terman JS, Terman M, Amira L (1994) One-week light treatment of winter depression near its onset: the time course of relapse. Depression 2:20–31Google Scholar
- Thorell LH, Kjellman B, Arned M, Lindwall-Sundel K, Walinder J, Wetterberg L (1999) Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. Int Clin Psychopharmacology 14[Suppl 2]:S7–S11Google Scholar
- Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Vitouch O, Asenbaum S, Brücke T, Tauscher J, Kasper S (2000) (123I)-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 47:482–489CrossRefPubMedGoogle Scholar
- Williams JBW, Link MJ, Rosenthal NE, Terman M (1988) Structured interview guide for the Hamilton depression rating scale, seasonal affective disorders version (SIGH-SAD). New York State Psychiatric Institute, New YorkGoogle Scholar
- Wirz-Justice A, Krauchi K, Brunner DB, Graw P, Haug H-J, Leonhardt G, Sarrafzadeh A, English J, Arendt J (1995) Circadian rhythms and sleep regulation in seasonal affective disorder. Acta Neuropsychiatr 7:41–43Google Scholar